Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eye disease in sickling disorders

S Charache1

  • 1Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Hematology/Oncology Clinics of North America
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

American journal of hematology·2000
Same author

Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.

Seminars in hematology·1997
Same author

Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.

Blood·1997
Same author

Experimental therapy.

Hematology/oncology clinics of North America·1996
Same author

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Medicine·1996
Same author

Treatment of sickling disorders.

Current opinion in hematology·1996

Hematologists and oncologists must recognize eye lesions in sickle cell disease patients. Immediate referral is needed for hyphema, while retinal neovascularization and vitreous hemorrhage also warrant referral.

Area of Science:

  • Ophthalmology
  • Hematology
  • Genetics

Background:

  • Sickling disorders, such as sickle cell disease, can affect various organs, including the eyes.
  • Ocular complications in these patients can lead to vision impairment if not managed promptly.

Purpose of the Study:

  • To delineate the spectrum of ocular lesions in patients with sickling disorders.
  • To guide hematologists and oncologists on appropriate referral pathways for specific eye conditions.

Main Methods:

  • Review of clinical presentations and ophthalmological findings in patients with hemoglobin S.
  • Categorization of eye lesions based on urgency for ophthalmological referral and potential for vision loss.

Main Results:

  • Hyphema requires immediate referral to an ophthalmologist.

Related Experiment Videos

  • Retinal neovascularization (proliferative retinopathy) and vitreous hemorrhage necessitate referral.
  • Comma sign, angioid streaks, and abnormal color vision are less frequently associated with vision decrease.

    • Conclusions:

    • Accurate identification of ocular manifestations is crucial for timely intervention in sickling disorders.
    • Understanding referral criteria for specific eye lesions can prevent irreversible vision loss.
    • Further research is needed on the efficacy of preoperative transfusion and antisickling therapies.